Literature DB >> 2991904

Ectopic peptides released by a human melanoma cell line that modulate the transformed phenotype.

J E De Larco, D A Pigott, J A Lazarus.   

Abstract

Cells derived from a human melanoma strain by low-serum selection in monolayer were found to be capable of growth in semisolid medium, forming colonies ranging from tight to loose or dispersed. These phenotypes were found to be stable after cloning and retesting. Examination of the biological activities of ectopic peptides produced by a clone that gives rise to loose dispersed colonies revealed the presence of a transforming growth factor beta (TGF-beta; apparent Mr 14,700) and a single TGF-alpha species produced at an unusually high concentration (2.2 ng/ml). Coeluted with the TGF-alpha at approximately 22,500 was a mitogenic activity and a previously undescribed activity capable of modulating the phenotype of induced normal rat kidney fibroblast (NRK-49F) colonies in semisolid medium. This activity can modulate the usual tight colony to express a loose or dispersed phenotype characteristic of the producer cells. Both the possible role these ectopic peptides play in the expression of the transformed phenotype by the tumor cells producing them and the possible correlation between the Mr 22,500 epidermal growth factor-like peptide released by this particular tumor line and high molecular weight epidermal growth factor-like peptides found in the urine of cancer patients are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991904      PMCID: PMC390489          DOI: 10.1073/pnas.82.15.5015

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Growth factors from murine sarcoma virus-transformed cells.

Authors:  J E de Larco; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

2.  Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization.

Authors:  C R Savage; S Cohen
Journal:  J Biol Chem       Date:  1972-12-10       Impact factor: 5.157

3.  Purification and initial characterization of a type beta transforming growth factor from human placenta.

Authors:  C A Frolik; L L Dart; C A Meyers; D M Smith; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

4.  Serum contains a platelet-derived transforming growth factor.

Authors:  C B Childs; J A Proper; R F Tucker; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

5.  Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells.

Authors:  M A Anzano; A B Roberts; C A Meyers; A Komoriya; L C Lamb; J M Smith; M B Sporn
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

6.  Kirsten murine sarcoma virus transformed cell lines and a spontaneously transformed rat cell-line produce transforming factors.

Authors:  B Ozanne; R J Fulton; P L Kaplan
Journal:  J Cell Physiol       Date:  1980-10       Impact factor: 6.384

7.  High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer.

Authors:  S A Sherwin; D R Twardzik; W H Bohn; K D Cockley; G J Todaro
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

8.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization.

Authors:  R K Assoian; A Komoriya; C A Meyers; D M Miller; M B Sporn
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

9.  Distinct high-performance liquid chromatography pattern of transforming growth factor activity in urine of cancer patients as compared with that of normal individuals.

Authors:  E S Kimball; W H Bohn; K D Cockley; T C Warren; S A Sherwin
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

10.  Human transforming growth factor. Production by a melanoma cell line, purification, and initial characterization.

Authors:  H Marquardt; G J Todaro
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

View more
  8 in total

1.  Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.

Authors:  M Luca; S Huang; J E Gershenwald; R K Singh; R Reich; M Bar-Eli
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines.

Authors:  A J Linnenbach; K Huebner; E P Reddy; M Herlyn; A H Parmiter; P C Nowell; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

3.  Identification of a synthetic nonapeptide sequence that inhibits motility in culture of a melanoma subclone that possesses a high metastatic potential.

Authors:  B S Packard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Smooth muscle releases an epithelial cell scatter factor which binds to heparin.

Authors:  E M Rosen; I D Goldberg; B M Kacinski; T Buckholz; D W Vinter
Journal:  In Vitro Cell Dev Biol       Date:  1989-02

Review 5.  Protein factors which regulate cell motility.

Authors:  E M Rosen; I D Goldberg
Journal:  In Vitro Cell Dev Biol       Date:  1989-12

Review 6.  Growth factors in melanoma.

Authors:  U Rodeck; M Herlyn
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 7.  Growth factor independence and growth regulatory pathways in human melanoma development.

Authors:  U Rodeck
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

8.  Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer.

Authors:  Günther Weber; Clara Ibel Chamorro; Fredrik Granath; Annelie Liljegren; Sami Zreika; Zuzana Saidak; Bengt Sandstedt; Samuel Rotstein; Romuald Mentaverri; Fabio Sánchez; Andor Pivarcsi; Mona Ståhle
Journal:  Breast Cancer Res       Date:  2009-01-30       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.